Advertisement
U.S. markets open in 3 hours 32 minutes

InspireMD, Inc. (NSPR)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
2.2700-0.0300 (-1.30%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close2.3000
Open2.1600
Bid2.5100 x 900
Ask2.6300 x 800
Day's Range2.1600 - 2.3600
52 Week Range0.9600 - 3.8500
Volume51,181
Avg. Volume29,386
Market Cap53.246M
Beta (5Y Monthly)0.85
PE Ratio (TTM)N/A
EPS (TTM)-0.8200
Earnings DateMay 14, 2024 - May 20, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.85
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NSPR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • InspireMD Inc.
    Analyst Report: Boston Scientific CorporationBoston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
    Rating
    Fair Value
    Economic Moat
    17 hours agoMorningstar
View more
  • Insider Monkey

    InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript

    InspireMD, Inc. (NASDAQ:NSPR) Q4 2023 Earnings Call Transcript March 6, 2024 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.2. InspireMD, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings. Welcome to InspireMD Fourth Quarter and […]

  • GlobeNewswire

    InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

    - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Prime - - Named Patrick Geraghty, M.D. and Patrick Muck, M.D. as lead principal investigators for the Company’s C-GUARDIANS II clinical trial of its SwitchGuard™ NPS for Transcarotid Artery Revascularization (TCAR),

  • GlobeNewswire

    InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

    -Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report fourth quarter and full-year 2023 financial results on Wednesday, March 6th, 2024, before the financial markets open. Management will host a conference call and webcast with the in